Related Experiment Video
Updated: Jan 25, 2026

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
Published on: July 22, 2019
The CRISPR-Cas9 Patent Appeal: Where Do We Go From Here?
Jacob S Sherkow1,2,3
11 Innovation Center for Law and Technology, New York Law School , New York, New York.
Abstract:
An appellate court in the United States affirmed the Patent Office's finding that the Broad Institute's patents covering eukaryotic applications of CRISPR-Cas9 was separately patentable over the University of California's (UC) earlier patent application. This does not bode well for future negotiations between UC and the Broad Institute, even as nuclease technology continues to eclipse the original dispute. This perspective explores the appellate decision, where UC goes from here, and what this all means for scientists in the future.
Related Concept Videos
CRISPR
CRISPR/Cas9 Genome Editing
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The Antiviral System of Bacteria and Archaea: CRISPR
What is Genetic Engineering?
Relationship Formation

